FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2762474926> ?p ?o ?g. }

• W2762474926 endingPage "93195" @default.
• W2762474926 startingPage "93186" @default.
• W2762474926 abstract "// Feng Liang 1, * , Yangxin Wang 2, * , Ligen Shi 1 and Jianmin Zhang 1 1 Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, ZheJiang University, HangZhou, ZheJiang 310009, China 2 Department of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, ZheJiang University, HangZhou, ZheJiang 310009, China * These authors contributed equally to this work Correspondence to: Jianmin Zhang, email: zjm135@zju.edu.cn Keywords: ezrin, gastrointestinal, cancer, prognosis Received: February 01, 2017      Accepted: September 21, 2017      Published: October 04, 2017 ABSTRACT Background: Ezrin, a cytoskeletal protein, is involved in cell adhesion. Several studies have been performed to explore the association between Ezrin and gastrointestinal cancers, but the results are inconclusive. This meta-analysis aims to assess the prognostic value of Ezrin. Materials and Methods/Findings: PubMed and EMBASE were searched. Pooled hazard ratio (HR), odds ratio (OR) and 95% confidence intervals (CI) were utilized to evaluate the association between Ezrin expression and various clinical parameters. 2701 patients from 19 studies were included in the meta-analysis. For gastric cancer, Ezrin expression was associated with tumor grade (OR 2.32, 95% CI 1.53–3.52), TNM stage (OR 4.69, 95% CI 1.38–15.89), lymph node involvement (OR 3.96, 95% CI 1.47–10.70) and overall survival (HR 1.88, 95% CI 1.33–2.66). In colorectal cancer, Ezrin expression was associated with tumor grade (OR 3.94, 95% CI 2.10–3.78), TNM stage (OR 5.66, 95% CI 1.41–22.67), lymph node metastasis (OR 9.52, 95% CI 3.93–23.02), distant metastasis (OR 3.06, 95% CI 1.77–5.31), disease free survival (HR 2.48, 95% CI 1.44–4.28). For esophageal cancer, Ezrin expression was associated with lymph node metastasis (OR 2.07, 95% CI 1.00–4.28) and overall survival (HR 1.49, 95% CI 1.17–1.89). Conclusions: Ezrin expression is significantly associated with tumor grade, TNM stage, and lymph node metastasis in gastric and colorectal cancers. For gastric cancers, Ezrin is useful in predicting distant metastasis. Survival data showed that high Ezrin expression is associated with poor prognosis in gastric, colorectal and esophageal cancers. Our findings suggest that Ezrin might be a potential biomarker in several gastrointestinal cancers." @default.
• W2762474926 created "2017-10-20" @default.
• W2762474926 creator A5002869526 @default.
• W2762474926 creator A5012394672 @default.
• W2762474926 creator A5079156452 @default.
• W2762474926 creator A5087309291 @default.
• W2762474926 date "2017-10-04" @default.
• W2762474926 modified "2023-09-25" @default.
• W2762474926 title "Association of Ezrin expression with the progression and prognosis of gastrointestinal cancer: a meta-analysis" @default.
• W2762474926 cites W1528557156 @default.
• W2762474926 cites W1531626472 @default.
• W2762474926 cites W1535108918 @default.
• W2762474926 cites W1968205541 @default.
• W2762474926 cites W1983222825 @default.
• W2762474926 cites W1991313260 @default.
• W2762474926 cites W2002521887 @default.
• W2762474926 cites W2002603913 @default.
• W2762474926 cites W2005252392 @default.
• W2762474926 cites W2011044506 @default.
• W2762474926 cites W2016655162 @default.
• W2762474926 cites W2024638949 @default.
• W2762474926 cites W2040149839 @default.
• W2762474926 cites W2042015318 @default.
• W2762474926 cites W2052358899 @default.
• W2762474926 cites W2060886359 @default.
• W2762474926 cites W2063238746 @default.
• W2762474926 cites W2068898588 @default.
• W2762474926 cites W2075629467 @default.
• W2762474926 cites W2084526459 @default.
• W2762474926 cites W2088095316 @default.
• W2762474926 cites W2106787323 @default.
• W2762474926 cites W2116475791 @default.
• W2762474926 cites W2120453365 @default.
• W2762474926 cites W2122570601 @default.
• W2762474926 cites W2147048296 @default.
• W2762474926 cites W2156098321 @default.
• W2762474926 cites W2159352516 @default.
• W2762474926 cites W2160551971 @default.
• W2762474926 cites W2161817637 @default.
• W2762474926 cites W2162577349 @default.
• W2762474926 cites W2312211630 @default.
• W2762474926 cites W2330746655 @default.
• W2762474926 cites W2353784670 @default.
• W2762474926 cites W2388852667 @default.
• W2762474926 cites W2403991102 @default.
• W2762474926 cites W246286872 @default.
• W2762474926 cites W2469339417 @default.
• W2762474926 cites W2605412109 @default.
• W2762474926 cites W4210995086 @default.
• W2762474926 cites W4294215472 @default.
• W2762474926 cites W2097618253 @default.
• W2762474926 doi "https://doi.org/10.18632/oncotarget.21473" @default.
• W2762474926 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5696254" @default.
• W2762474926 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29190988" @default.
• W2762474926 hasPublicationYear "2017" @default.
• W2762474926 type Work @default.
• W2762474926 sameAs 2762474926 @default.
• W2762474926 citedByCount "10" @default.
• W2762474926 countsByYear W27624749262019 @default.
• W2762474926 countsByYear W27624749262020 @default.
• W2762474926 countsByYear W27624749262023 @default.
• W2762474926 crossrefType "journal-article" @default.
• W2762474926 hasAuthorship W2762474926A5002869526 @default.
• W2762474926 hasAuthorship W2762474926A5012394672 @default.
• W2762474926 hasAuthorship W2762474926A5079156452 @default.
• W2762474926 hasAuthorship W2762474926A5087309291 @default.
• W2762474926 hasBestOaLocation W27624749261 @default.
• W2762474926 hasConcept C121608353 @default.
• W2762474926 hasConcept C126322002 @default.
• W2762474926 hasConcept C142669718 @default.
• W2762474926 hasConcept C143998085 @default.
• W2762474926 hasConcept C1491633281 @default.
• W2762474926 hasConcept C156957248 @default.
• W2762474926 hasConcept C207103383 @default.
• W2762474926 hasConcept C2780246058 @default.
• W2762474926 hasConcept C44249647 @default.
• W2762474926 hasConcept C54355233 @default.
• W2762474926 hasConcept C71924100 @default.
• W2762474926 hasConcept C86803240 @default.
• W2762474926 hasConcept C95190672 @default.
• W2762474926 hasConceptScore W2762474926C121608353 @default.
• W2762474926 hasConceptScore W2762474926C126322002 @default.
• W2762474926 hasConceptScore W2762474926C142669718 @default.
• W2762474926 hasConceptScore W2762474926C143998085 @default.
• W2762474926 hasConceptScore W2762474926C1491633281 @default.
• W2762474926 hasConceptScore W2762474926C156957248 @default.
• W2762474926 hasConceptScore W2762474926C207103383 @default.
• W2762474926 hasConceptScore W2762474926C2780246058 @default.
• W2762474926 hasConceptScore W2762474926C44249647 @default.
• W2762474926 hasConceptScore W2762474926C54355233 @default.
• W2762474926 hasConceptScore W2762474926C71924100 @default.
• W2762474926 hasConceptScore W2762474926C86803240 @default.
• W2762474926 hasConceptScore W2762474926C95190672 @default.
• W2762474926 hasIssue "54" @default.
• W2762474926 hasLocation W27624749261 @default.
• W2762474926 hasLocation W27624749262 @default.
• W2762474926 hasLocation W27624749263 @default.
• W2762474926 hasLocation W27624749264 @default.

• next